Antiviral_JJ Activities_NNS of_IN MCC-478_NP ,_, a_DT Novel_NP and_CC Specific_NP Inhibitor_NP of_IN Hepatitis_NP B_NP Virus_NP MCC-478_NP is_VBZ a_DT newly_RB synthesized_VBN 2-amino-6-arylthio-9-phosphonomethoxyethylpurine_JJ bis(2,2,2-trifluoroethyl)_JJ ester_NN derivative_NN ._SENT MCC-478_NP showed_VBD a_DT substantially_RB higher_JJR (_( ca_MD ._SENT 80-fold_NN )_) anti-hepatitis_NN B_NN virus_NN (_( HBV_NP )_) activity_NN than_IN that_DT of_IN lamivudine_NP ,_, despite_IN no_DT significant_JJ anti-human_NN immunodeficiency_NN virus_NN activity_NN ._SENT Since_IN the_DT bis(2,2,2-trifluoroethyl)_JJ ester_NN group_NN was_VBD used_VBN to_TO improve_VB the_DT oral_JJ bioavailability_NN of_IN the_DT phosphonomethoxyethylpurine_NN derivatives_NNS ,_, two_CD monoester_NN derivatives_NNS and_CC one_CD phosphonic_JJ acid_JJ derivative_NN were_VBD also_RB evaluated_VBN ._SENT It_PP was_VBD suggested_VBN that_IN these_DT hydrolyzed_VBN derivatives_NNS ,_, which_WDT appeared_VBD in_IN animals_NNS given_VBN MCC-478_NP ,_, have_VBP enough_JJ anti-HBV_NP activity_NN to_TO contribute_VB to_TO efficacy_NN in_IN vivo_RB ._SENT Furthermore_RB ,_, no_DT apparent_JJ cytotoxic_JJ effects_NNS or_CC reductions_NNS of_IN mitochondrial_JJ DNA_NN content_NN by_IN MCC-478_NP and_CC its_PP$ derivatives_NNS were_VBD observed_VBN ._SENT These_DT results_NNS indicated_VBD that_IN MCC-478_NP may_MD be_VB a_DT new_JJ promising_JJ anti-HBV_NN agent_NN ._SENT Hepatitis_NP B_NP virus_NN (_( HBV_NP )_) is_VBZ a_DT small_JJ ,_, partially_RB double-stranded_JJ DNA_NN virus_NN and_CC a_DT prototype_NN member_NN of_IN the_DT hepadnavirus_NN family_NN ._SENT HBV_NP is_VBZ a_DT causative_JJ agent_NN of_IN both_DT acute_JJ and_CC chronic_JJ hepatitis_NN ._SENT The_DT World_NP Health_NP Organization_NP lists_VBZ hepatitis_NP B_NP as_IN one_CD of_IN the_DT 10_CD leading_VBG killer_NN diseases_NNS and_CC estimates_VBZ that_IN 350_CD million_CD people_NNS are_VBP chronically_RB infected_VBN with_IN HBV_NP ._SENT Until_IN 1999_CD the_DT only_JJ therapy_NN approved_VBN for_IN chronic_JJ HBV_NP infection_NN was_VBD alpha_NN interferon_NN ,_, and_CC this_DT treatment_NN was_VBD useful_JJ only_RB for_IN a_DT small_JJ minority_NN of_IN Asian_JJ patients_NNS ._SENT The_DT hepadnavirus_NN has_VBZ a_DT unique_JJ replication_NN cycle_NN ._SENT Following_VBG entry_NN into_IN a_DT hepatocyte_NN ,_, the_DT viral_JJ genome_NN matures_VBZ to_TO a_DT single_JJ covalently_NN closed_VBD circular_JJ DNA_NN by_IN an_DT unknown_JJ enzyme_NN derived_VBN from_IN the_DT host_NN cell_NN and/or_CC hepadnavirus_NN polymerase_NN ._SENT The_DT covalently_NN closed_VBD circular_JJ DNA_NN is_VBZ translocated_VBN into_IN the_DT nucleus_NN and_CC serves_VBZ as_IN the_DT template_NN for_IN several_JJ viral_JJ RNAs_NP ._SENT A_DT hepadnavirus_NN polymerase_NN ,_, which_WDT is_VBZ encoded_VBN by_IN a_DT gene_NN in_IN the_DT longest_JJS 3.5-kb_JJ pregenome_NN RNA_NP ,_, transcribes_VBZ full-length_JJ negative-strand_NN HBV_NP genome_NN from_IN a_DT pregenome_JJ RNA_NP within_IN nucleocapsids_NNS ._SENT Sequentially_RB ,_, the_DT polymerase_NN exerts_VBZ its_PP$ DNA-dependent_NP DNA_NP polymerase_NN activity_NN to_TO synthesize_VB the_DT positive-strand_NN HBV_NP genome_NN ._SENT Since_IN the_DT replication_NN cycle_NN of_IN hepadnavirus_NN genome_NN is_VBZ dependent_JJ upon_IN the_DT action_NN of_IN its_PP$ own_JJ polymerase_NN ,_, HBV_NP polymerase_NN could_MD be_VB a_DT good_JJ target_NN for_IN an_DT antiviral_JJ therapy_NN ._SENT Recently_RB ,_, lamivudine_NP was_VBD approved_VBN to_TO treat_VB chronic_JJ HBV_NP infection_NN ._SENT Lamivudine_NP is_VBZ a_DT dideoxycytidine_NP analogue_NN that_WDT is_VBZ active_JJ against_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) and_CC HBV_NP ._SENT It_PP is_VBZ also_RB shown_VBN that_IN lamivudine_NP triphosphate_NN acts_NNS as_IN a_DT chain_NN terminator_NN against_IN viral_JJ DNA_NN synthesis_NN ._SENT However_RB ,_, prolonged_JJ lamivudine_NP treatment_NN results_NNS in_IN the_DT emergence_NN of_IN lamivudine-resistant_JJ HBV_NP mutants_NNS in_IN 17_CD to_TO 46_CD %_NN of_IN patients_NNS treated_VBN for_IN 1_CD year_NN and_CC more_JJR than_IN 50_CD %_NN of_IN patients_NNS within_IN 2_CD years_NNS of_IN treatment_NN ._SENT The_DT emergence_NN of_IN drug-resistant_JJ HBV_NP emphasizes_VBZ the_DT need_NN to_TO develop_VB other_JJ antiviral_JJ agents_NNS and_CC therapeutic_JJ strategies_NNS ._SENT One_CD of_IN the_DT candidates_NNS ,_, adefovir_NN dipivoxil_NN ,_, which_WDT is_VBZ an_DT oral_JJ prodrug_NN of_IN adefovir_NN (_( PMEA_NP )_) and_CC is_VBZ active_JJ against_IN HIV_NP and_CC HBV_NP replication_NN ,_, is_VBZ now_RB in_IN phase_NN III_NP clinical_JJ trials_NNS to_TO treat_VB HBV_NP infection_NN ._SENT Although_IN adefovir_NN dipivoxil_NN is_VBZ suggested_VBN to_TO be_VB active_JJ against_IN lamivudine-resistant_JJ HBV_NP strains_NNS ,_, nephrotoxicity_NN ,_, characterized_VBN by_IN changes_NNS in_IN renal_JJ function_NN laboratory_NN markers_NNS ,_, is_VBZ observed_VBN among_IN HIV_NP patients_NNS treated_VBD long-term_JJ with_IN adefovir_NN dipivoxil_NN ._SENT We_PP synthesized_VBD more_JJR than_IN 100_CD derivatives_NNS of_IN phosphonomethoxyethylpurine_NN and_CC evaluated_VBD anti-HBV_NP activity_NN ._SENT The_DT absorbability_NN of_IN test_NN compounds_NNS was_VBD also_RB examined_VBN using_VBG ex_JJ vivo_JJ samples_NNS from_IN mice_NNS and_CC rats_NNS given_VBN the_DT drug_NN orally_RB ._SENT Finally_RB ,_, we_PP found_VBD 2-amino-6-arylthio-9-phosphonomethoxyethylpurine_JJ bis(2,2,2-trifluoroethyl)_JJ ester_NN derivatives_NNS that_WDT showed_VBD high_JJ antiviral_JJ activity_NN and_CC apparent_JJ absorption_NN in_IN the_DT animals_NNS ._SENT In_IN this_DT report_NN ,_, we_PP evaluated_VBD the_DT in_IN vitro_NP antiviral_JJ properties_NNS of_IN MCC-478_NP ,_, 2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine_JJ bis(2,2,2-trifluoroethyl)_JJ ester_NN ._SENT Since_IN the_DT bis(2,2,2-trifluoroethyl)_JJ ester_NN group_NN was_VBD used_VBN to_TO improve_VB the_DT oral_JJ bioavailability_NN of_IN the_DT phosphonomethoxyethylpurine_NN derivatives_NNS and_CC might_MD be_VB hydrolyzed_VBN in_IN vivo_JJ to_TO give_VB its_PP$ monoester_NN and_CC free_JJ phosphonic_JJ acid_NN ,_, the_DT monoester_NN and_CC free_JJ phosphonic_JJ acid_NN derivatives_NNS of_IN MCC-478_NP were_VBD also_RB tested_VBN ._SENT In_IN order_NN to_TO investigate_VB the_DT toxicological_JJ profile_NN of_IN MCC-478_NP ,_, cytotoxicity_NN and_CC reduction_NN of_IN the_DT mitochondrial_JJ DNA_NN content_NN was_VBD evaluated_VBN ._SENT It_PP was_VBD shown_VBN that_IN MCC-478_NP is_VBZ a_DT potent_JJ inhibitor_NN of_IN HBV_NP replication_NN ,_, and_CC its_PP$ antiviral_JJ profile_NN is_VBZ specific_JJ to_TO HBV_NP ._SENT Compounds_NNS ._SENT |_SYM The_DT following_VBG test_NN compounds_NNS were_VBD chemically_RB synthesized_VBN at_IN Mitsubishi_NP Pharma_NP Corporation_NP :_: MCC-478_JJ (2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine_NN bis(2,2,2-trifluoroethyl)_NN ester_NN )_) ,_, monoester_NN derivative_NN 1_CD (_( M-1_NP )_) (2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine_NN 2,2,2-trifluoroethyl_JJ ester_NN )_) ,_, free_JJ phosphonic_JJ acid_NN derivative_NN 1_CD (_( F-1_NP )_) (2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine)_NN ,_, and_CC monoester_NN derivative_NN 2_CD (_( M-2_NP )_) (2-amino-6-(4-hydroxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine_NN 2,2,2-trifluoroethyl_JJ ester_NN )_) ._SENT PMEA_NP (9-[2-(phosphonomethoxy)ethyl]adenine)_NP was_VBD synthesized_VBN by_IN the_DT method_NN of_IN Holy_NP and_CC Rosenberg_NP ._SENT Lamivudine_NP was_VBD extracted_VBN and_CC purified_VBN from_IN tablets_NNS of_IN Epivir_NP (_( GlaxoWellcome_NP )_) ._SENT Epivir_NP tablets_NNS (_( 60_CD 150-mg_NP tablets_NNS )_) were_VBD ground_VBN and_CC extracted_VBN with_IN hot_JJ methanol_NN ._SENT Silica_NN gel_NN was_VBD added_VBN to_TO this_DT methanol_NN solution_NN ,_, and_CC the_DT resultant_JJ slurry_NN was_VBD stirred_VBN for_IN 30_CD min_NN ._SENT Methanol_NN was_VBD removed_VBN by_IN evaporation_NN ,_, and_CC the_DT residue_NN was_VBD transferred_VBN to_TO a_DT silica_NN gel_NN column_NN ._SENT The_DT desired_VBN material_NN was_VBD eluted_VBN with_IN a_DT 9:1_CD mixture_NN of_IN chloroform-methanol_NN ._SENT The_DT eluate_NN was_VBD concentrated_VBN and_CC dissolved_VBN in_IN methanol-toluene_NN to_TO produce_VB crystals_NNS of_IN lamivudine_NP ._SENT The_DT yield_NN was_VBD 8.14_CD g._FW The_DT structure_NN was_VBD identified_VBN with_IN proton_NN nuclear_JJ magnetic_JJ resonance_NN ,_, and_CC the_DT purity_NN (_( >99_JJ %_NN )_) was_VBD checked_VBN by_IN thin-layer_JJ chromatography_NN ,_, high-pressure_JJ liquid_JJ chromatography_NN ,_, and_CC measurement_NN of_IN optical_JJ rotation_NN ._SENT The_DT structures_NNS of_IN MCC-478_NP ,_, M-1_NP ,_, M-2_NP ,_, F-1_NP ,_, and_CC PMEA_NP are_VBP shown_VBN in_IN Fig._NN ._SENT Cell_NN culture_NN ._SENT |_SYM HB611_NP ,_, a_DT stably_RB transfected_JJ cell_NN line_NN which_WDT contains_VBZ three_CD copies_NNS of_IN the_DT HBV_NP genome_NN in_IN tandem_NN in_IN its_PP$ chromosome_NN ,_, and_CC HuH-6_NP ,_, a_DT parent_NN cell_NN line_NN ,_, were_VBD kindly_RB provided_VBN by_IN K._NP Matsubara_NP (_( Institute_NP for_IN Molecular_NP and_CC Cellular_NP Biology_NP ,_, Osaka_NP University_NP ,_, Osaka_NP ,_, Japan_NP ;_: now_RB at_IN the_DT Department_NP of_IN Molecular_NP Biology_NP ,_, Nara_NP Institute_NP of_IN Science_NP and_CC Technology_NP ,_, Nara_NP ,_, Japan_NP )_) ._SENT HB611_JJ cells_NNS were_VBD maintained_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP )_) supplemented_VBD with_IN 0.2_CD mg_NN of_IN Geneticin_NP (_( GibcoBRL_NP )_) per_IN ml_NN and_CC 10_CD %_NN fetal_JJ calf_NN serum_NN (_( FCS_NN )_) ._SENT HuH-6_NP cells_NNS were_VBD maintained_VBN in_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN FCS_NN ._SENT HepG2_JJ cells_NNS were_VBD obtained_VBN from_IN Dainippon_NP Pharmaceuticals_NPS (_( Osaka_NP ,_, Japan_NP )_) and_CC maintained_VBN in_IN MEM_NP supplemented_VBD with_IN nonessential_JJ amino_NN acids_NNS ,_, 1_CD mM_NP sodium_NN pyruvate_NNS ,_, and_CC 10_CD %_NN FCS_NN ._SENT All_DT cell_NN lines_NNS were_VBD cultured_VBN at_IN 37C_JJ with_IN 5_CD %_NN CO2_NN ._SENT Analysis_NN of_IN anti-HBV_NP activities_NNS ._SENT |_SYM Antiviral_JJ activities_NNS of_IN the_DT test_NN compounds_NNS were_VBD analyzed_VBN by_IN a_DT modified_JJ version_NN of_IN the_DT method_NN of_IN Yokota_NP et_FW al._FW ._SENT HB611_JJ cells_NNS were_VBD plated_VBN at_IN a_DT density_NN of_IN 2_CD x_NN 104_CD cells_NNS per_IN well_RB on_IN 24-well_JJ plates_NNS ._SENT When_WRB the_DT cells_NNS had_VBD grown_VBN to_TO confluence_NN ,_, the_DT medium_NN was_VBD changed_VBN to_TO medium_NN containing_VBG a_DT test_NN compound_NN ._SENT Test_NN compounds_NNS and_CC the_DT final_JJ concentrations_NNS in_IN the_DT experiments_NNS were_VBD as_RB follows_VBZ :_: experiment_NN 1_CD ,_, MCC-478_NP at_IN 0.01_CD ,_, 0.03_CD ,_, 0.1_CD ,_, 0.3_CD ,_, 1.0_CD ,_, and_CC 3.0_CD muM_NN and_CC PMEA_NP and_CC lamivudine_NP at_IN 0.1_CD ,_, 0.3_CD ,_, 1.0_CD ,_, 3.0_CD ,_, and_CC 10_CD muM_NN ;_: experiment_NN 2_CD ,_, MCC-478_NP ,_, M-1_NP ,_, and_CC F-1_NP at_IN 0.01_CD ,_, 0.03_CD ,_, 0.1_CD ,_, 0.3_CD ,_, and_CC 1.0_CD muM_NN ;_: experiment_NN 3_CD ,_, M-1_NP and_CC M-2_NP at_IN 0.03_CD ,_, 0.1_CD ,_, 0.3_CD ,_, 1.0_CD ,_, and_CC 3.0_CD muM_NN ._SENT The_DT cells_NNS were_VBD cultured_VBN for_IN 8_CD or_CC 9_CD days_NNS with_IN the_DT drug-containing_NN medium_NN changed_VBD every_DT 3_CD or_CC 4_CD days_NNS ._SENT On_IN the_DT last_JJ day_NN of_IN cultivation_NN ,_, the_DT monolayers_NNS were_VBD washed_VBN with_IN phosphate-buffered_JJ saline_NN ,_, and_CC the_DT cells_NNS were_VBD lysed_VBN at_IN 37C_JJ for_IN 1_CD h_NN with_IN 0.5_CD ml_NN of_IN lysis_NN buffer_NN (_( 10_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 5_CD mM_NP EDTA_NP ,_, 1_CD %_NN sodium_NN dodecyl_JJ sulfate_NN [_SYM SDS_NP ]_SYM ,_, 0.1_CD mg_NN of_IN proteinase_NN K_NP [_SYM Boehringer_NP Mannheim_NP ]_SYM per_FW ml_NN )_) ._SENT The_DT lysates_NNS were_VBD collected_VBN and_CC placed_VBN in_IN 1.5-ml_JJ Eppendorf_NP tubes_NNS and_CC were_VBD further_RBR digested_VBN by_IN proteinase_NN K_NN for_IN 2_CD days_NNS with_IN gentle_JJ agitation_NN ._SENT After_IN digestion_NN with_IN 0.1_CD mg_NN of_IN RNase_NP A_NP per_IN ml_NN at_IN 65C_JJ for_IN 15_CD min_NN ,_, the_DT lysate_NN was_VBD extracted_VBN by_IN phenol-chloroform-isoamyl_NN alcohol_NN ._SENT The_DT total_JJ cellular_JJ DNA_NN was_VBD precipitated_VBN by_IN ethanol_NN and_CC was_VBD digested_VBN with_IN HindIII_NP (_( Boehringer_NP Mannheim_NP )_) at_IN 37C_JJ overnight_JJ ._SENT The_DT digested_VBN DNA_NN was_VBD electrophoresed_VBN on_IN a_DT 0.9_CD %_NN agarose-1x_NN Tris-borate-EDTA_NP gel_NN and_CC stained_VBN with_IN ethidium_NN bromide_NN ._SENT The_DT separated_JJ DNA_NN samples_NNS were_VBD treated_VBN with_IN 0.25_CD N_NP hydrochloric_JJ acid_NN for_IN 15_CD min_NN ,_, denatured_VBN in_IN 0.5_CD N_NP NaOH_NP for_IN 30_CD min_NN ,_, and_CC neutralized_VBN with_IN 0.5_CD M_NP Tris-HCl_NP [_SYM pH_NN 7.5_CD ]_SYM containing_VBG 1.5_CD M_NP NaCl_NP and_CC 1_CD mM_NP EDTA_NP for_IN 1_CD h._JJ DNA_NN was_VBD transferred_VBN to_TO a_DT nylon_NN membrane_NN (_( Hybond_NP N+_NP ;_: Amersham_NP )_) using_VBG a_DT VacuGene_NP vacuum_NN blotting_VBG system_NN (_( Amersham_NP )_) ._SENT The_DT membranes_NNS were_VBD dried_VBN ,_, linked_VBN by_IN using_VBG a_DT UV_NP illuminator_NN ,_, and_CC hybridized_VBD to_TO a_DT digoxigenin_NN (DIG)-labeled_VBD HBV_NP DNA_NP at_IN 42C_JJ overnight_JJ in_IN hybridization_NN buffer_NN (_( DIG_NP Easy_NP Hyb_NP ;_: Boehringer_NP Mannheim_NP )_) ._SENT The_DT hybridized_VBN membranes_NNS were_VBD washed_VBN twice_RB with_IN 2x_NP SSC_NP (_( 1x_NP SSC_NP is_VBZ 0.15_CD M_NP NaCl_NP plus_CC 0.015_CD M_NP sodium_NN citrate_NN )_) containing_VBG 0.1_CD %_NN SDS_NP at_IN room_NN temperature_NN for_IN 5_CD min_NN and_CC twice_RB with_IN 0.1x_NN SSC_NN containing_VBG 1_CD %_NN SDS_NP at_IN 65C_JJ for_IN 30_CD min_NN ._SENT The_DT HBV-specific_NP bands_NNS were_VBD detected_VBN by_IN anti-DIG-AP_NP Fab_NP fragments_VBZ (_( Boehringer_NP Mannheim_NP )_) and_CC CDP-star_NP (_( New_NP England_NP Biolabs_NP )_) ._SENT After_IN exposure_NN to_TO X-ray_NN film_NN (_( XJB_NP ;_: Kodak_NP )_) ,_, the_DT developed_JJ film_NN was_VBD scanned_VBN in_IN a_DT quantitative_JJ densitometric_JJ manner_NN using_VBG ImageQuant_NP image_NN analysis_NN software_NN on_IN a_DT Personal_NP Densitometer_NP (_( Molecular_NP Dynamics_NPS )_) ._SENT The_DT densities_NNS of_IN the_DT signals_NNS derived_VBN from_IN integrated_JJ HBV_NP and_CC free_JJ HBV_NP DNA_NP were_VBD measured_VBN ._SENT HBV_NP DNA_NP content_NN of_IN each_DT sample_NN was_VBD determined_VBN by_IN the_DT ratio_NN of_IN HBV_NP DNA_NP replication_NN intermediates_NNS to_TO integrated_JJ HBV_NP DNA_NP ._SENT Cytotoxicity_NN ._SENT |_SYM HuH-6_NP cells_NNS were_VBD plated_VBN at_IN a_DT density_NN of_IN 105_CD cells_NNS per_IN ml_NN on_IN 96-well_NN plates_NNS and_CC cultured_VBN at_IN 37C_JJ with_IN 5_CD %_NN CO2_NN for_IN 3_CD days_NNS in_IN DMEM_NP supplemented_VBD with_IN 10_CD %_NN FCS_NN and_CC each_DT test_NN compound_NN at_IN final_JJ concentrations_NNS of_IN 10_CD ,_, 30_CD ,_, 100_CD ,_, 300_CD ,_, and_CC 1,000_CD muM_NN ._SENT 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium_NP (_( MTS_NP )_) (_( CellTiter96_NP aqueous_JJ nonradioactive_JJ cell_NN proliferation_NN assay_NN ;_: Promega_NP )_) was_VBD added_VBN at_IN the_DT end_NN of_IN the_DT culture_NN period_NN ,_, and_CC the_DT plate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD h._NNS The_DT absorbance_NN at_IN 490_CD nm_NN of_IN each_DT well_NN was_VBD measured_VBN with_IN a_DT microplate_NN reader_NN (_( NJ-2000_NP ;_: Intermed_NP )_) ._SENT Anti-HIV_JJ activity_NN ._SENT |_SYM Determination_NN of_IN antiviral_JJ activity_NN against_IN HIV_NP type_NN 1_CD (_( HIV-1_NP )_) replication_NN was_VBD based_VBN on_IN inhibition_NN of_IN the_DT HIV-induced_JJ cytopathic_JJ effect_NN in_IN MT-4_NP cells_NNS ,_, as_RB described_VBN previously_RB ._SENT MT-4_JJ cells_NNS (_( 105/ml_NP )_) were_VBD infected_VBN with_IN HIV-1_NP (_( HTLV-IIIB_NP strain_NN )_) at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 0.02_CD ._SENT The_DT cells_NNS were_VBD cultured_VBN in_IN the_DT presence_NN of_IN 0.032_CD ,_, 0.16_CD ,_, 0.8_CD ,_, 4_CD ,_, and_CC 20_CD mug_NN of_IN the_DT test_NN compounds_NNS per_IN ml_NN at_IN 37C_JJ with_IN 5_CD %_NN CO2_NN ._SENT In_IN order_NN to_TO assess_VB the_DT viability_NN of_IN both_DT HIV-_NP and_CC mock-infected_JJ MT-4_JJ cells_NNS ,_, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium_JJ bromide_NN (_( MTT_NP )_) was_VBD added_VBN on_IN day_NN 4_CD after_IN virus_NN infection_NN and_CC incubated_VBN at_IN 37C_JJ for_IN 2_CD h._NNS The_DT absorbance_NN at_IN 540_CD nm_NN was_VBD measured_VBN ,_, and_CC the_DT percent_NN inhibition_NN value_NN was_VBD calculated_VBN ._SENT Mitochondrial_JJ DNA_NN content_NN ._SENT |_SYM HepG2_NP cells_NNS (_( 2.5_CD x_SYM 104_CD cells/well_NN )_) were_VBD plated_VBN in_IN a_DT 12-well_NP plate_NN and_CC treated_VBN with_IN each_DT test_NN compound_NN for_IN 8_CD days_NNS ._SENT On_IN the_DT last_JJ day_NN of_IN culture_NN ,_, the_DT cells_NNS were_VBD washed_VBN with_IN phosphate-buffered_JJ saline_NN ,_, harvested_VBN ,_, placed_VBN in_IN a_DT 1.5-ml_JJ Eppendorf_NP tube_NN ,_, and_CC stored_VBD at_IN -80C_NN until_IN use_NN ._SENT Cells_NNS were_VBD lysed_VBN and_CC digested_VBN by_IN proteinase_NN K_NN at_IN 37C_JJ for_IN one_CD night_NN with_IN lysis_NN buffer_NN ._SENT The_DT lysate_NN was_VBD digested_VBN with_IN RNase_NP A_NP (_( 0.1_CD mg/ml_NN )_) at_IN 65C_JJ for_IN 10_CD min_NN and_CC extracted_VBN by_IN phenol-chloroform-isoamyl_NN alcohol_NN ._SENT The_DT total_JJ cellular_JJ DNA_NN was_VBD precipitated_VBN by_IN ethanol_NN and_CC dissolved_VBN in_IN distilled_JJ water_NN ._SENT DNA_NP (_( 2.5_CD mug_NN )_) was_VBD denatured_VBN in_IN 0.5_CD N_NP NaOH_NP and_CC 1.5_CD M_NP sodium_NN chloride_NN for_IN 10_CD min_NN and_CC dot_NN blotted_VBN onto_IN a_DT nylon_NN membrane_NN (_( Hybond_NP N+_NP ;_: Amersham_NP )_) ._SENT The_DT membrane_NN was_VBD dried_VBN ,_, linked_VBN by_IN using_VBG a_DT UV_NP illuminator_NN ,_, and_CC hybridized_VBD to_TO a_DT DIG-labeled_JJ mitochondrion-specific_JJ oligonucleotide_NN DNA_NN probe_NN (_( 5'-DIG-CTTATATGAT_NP ATGTCTCCAT_NP ACCCATTACA_NP ATCTCCAGCA-3_NP '_POS )_) ,_, which_WDT extends_VBZ from_IN nucleotides_NNS 4207_CD to_TO 4246_CD of_IN mitochondrial_JJ DNA_NN ,_, in_IN the_DT hybridization_NN buffer_NN (_( DIG_NP Easy_NP Hyb_NP ;_: Boehringer_NP Mannheim_NP )_) at_IN 42C_JJ overnight_JJ ._SENT FIG._NN 1_CD ._SENT |_SYM Chemical_NP structures_NNS of_IN MCC-478_NP and_CC its_PP$ metabolites_NNS in_IN vivo_RB ._SENT Chemical_NN structures_NNS of_IN MCC-478_NP and_CC its_PP$ metabolites_NNS in_IN vivo_RB ._SENT Antiviral_JJ activities_NNS of_IN MCC-478_NP and_CC other_JJ nucleoside_NN or_CC nucleotide_NN analogues_NNS ._SENT |_SYM We_PP first_RB attempted_VBD to_TO evaluate_VB anti-HBV_NP activities_NNS of_IN MCC-478_NP ,_, lamivudine_NP ,_, and_CC PMEA_NP in_IN HB611_NP cells_NNS ,_, which_WDT is_VBZ a_DT stable_JJ transfected_JJ cell_NN line_NN producing_VBG HBV_NP ._SENT HB611_JJ cells_NNS were_VBD treated_VBN with_IN various_JJ concentrations_NNS of_IN MCC-478_NP ,_, lamivudine_NP ,_, or_CC PMEA_NP (_( both_CC lamivudine_NP and_CC PMEA_NP are_VBP used_VBN as_IN reference_NN drugs_NNS in_IN many_JJ studies_NNS for_IN anti-HBV_NP agents_NNS )_) ._SENT The_DT cells_NNS in_IN five_CD wells_NNS on_IN a_DT 24-well_JJ plate_NN were_VBD treated_VBN independently_RB at_IN each_DT concentration_NN for_IN 8_CD days_NNS ._SENT The_DT extent_NN of_IN HBV_NP DNA_NP replication_NN in_IN cells_NNS was_VBD evaluated_VBN from_IN the_DT ratio_NN of_IN the_DT replicative_JJ intermediates_NNS to_TO the_DT integrated_JJ HBV_NP genome_NN ._SENT Antiviral_JJ effects_NNS were_VBD reported_VBN as_IN percent_NN control_NN values_NNS (_( untreated_JJ cells_NNS )_) ._SENT Figure_NN shows_VBZ the_DT average_JJ percent_NN control_NN values_NNS of_IN HBV_NP DNA_NP replication_NN in_IN cells_NNS treated_VBN with_IN drugs_NNS at_IN each_DT concentration_NN ._SENT Also_RB ,_, WinNonlin_NP version_NN 1.1_CD (_( Scientific_NP Consulting_NP Inc._NP )_) was_VBD used_VBN to_TO calculate_VB the_DT 50_CD %_NN and_CC 90_CD %_NN effective_JJ concentrations_NNS (_( EC50_NP and_CC EC90_NP ,_, respectively_RB )_) of_IN MCC-478_NP and_CC lamivudine_NP ._SENT The_DT EC50_NP and_CC EC90_NP of_IN MCC-478_NP were_VBD 0.027_CD and_CC 0.24_CD muM_NN ,_, respectively_RB ,_, while_IN those_DT of_IN lamivudine_NP were_VBD 2.2_CD and_CC 7.8_CD muM_NN ,_, respectively_RB ._SENT The_DT EC50_NP of_IN PMEA_NP could_MD not_RB be_VB calculated_VBN ,_, since_IN PMEA_NP gave_VBD percent_NN control_NN values_NNS below_IN 50_CD even_RB at_IN the_DT lowest_JJS concentration_NN (_( 0.1_CD muM_NN )_) ._SENT These_DT results_NNS clearly_RB suggested_VBD that_IN MCC-478_NP was_VBD a_DT potent_JJ inhibitor_NN of_IN HBV_NP DNA_NP replication_NN ._SENT Comparison_NN of_IN the_DT anti-HBV_NP activities_NNS of_IN the_DT hydrolyzed_VBN derivatives_NNS of_IN MCC-478_NP ._SENT |_SYM Anti-HBV_NN activity_NN was_VBD also_RB observed_VBN in_IN sera_NN from_IN mice_NNS given_VBN MCC-478_JJ orally_RB (_( data_NNS not_RB shown_VBN )_) ._SENT Since_IN some_DT of_IN the_DT bisalkyl_NN ester_NN prodrugs_NNS of_IN PMEA_NP were_VBD not_RB cleaved_VBN completely_RB to_TO a_DT free_JJ phosphonic_JJ acid_NN form_NN ,_, two_CD monoester_NN derivatives_NNS (_( M-1_NP and_CC M-2_NP )_) and_CC one_CD phosphonic_JJ acid_JJ derivative_NN (_( F-1_NP )_) of_IN MCC-478_NP were_VBD putative_JJ metabolites_NNS in_IN serum_NN ._SENT In_IN order_NN to_TO understand_VB their_PP$ contribution_NN to_TO efficacy_NN in_IN vivo_RB ,_, they_PP were_VBD synthesized_VBN and_CC tested_VBN in_IN HB611_JJ cells_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT anti-HBV_NP activities_NNS of_IN M-1_NP and_CC F-1_NP were_VBD similar_JJ to_TO that_DT of_IN MCC-478_NP ,_, and_CC the_DT anti-HBV_NP activity_NN of_IN M-2_NP was_VBD similar_JJ to_TO that_DT of_IN M-1_NP ._SENT Cytotoxicity_NP and_CC anti-HIV_NP activity_NN of_IN MCC-478_NP ._SENT |_SYM The_DT 50_CD %_NN cytotoxic_JJ concentration_NN (_( CC50_NP )_) of_IN each_DT test_NN compound_NN was_VBD determined_VBN in_IN the_DT HuH-6_NP cell_NN line_NN ,_, the_DT parent_NN cell_NN line_NN of_IN HB611_NP ._SENT MCC-478_NP and_CC its_PP$ derivatives_NNS were_VBD well_RB tolerated_VBN ._SENT To_TO evaluate_VB the_DT specificity_NN for_IN antiviral_JJ activity_NN ,_, anti-HIV_NP activities_NNS of_IN MCC-478_NP ,_, PMEA_NP ,_, and_CC lamivudine_NP were_VBD determined_VBN by_IN examining_VBG the_DT inhibition_NN of_IN the_DT HIV-induced_JJ cytopathic_JJ effect_NN in_IN the_DT MT-4_NP cell_NN line_NN ._SENT Treatment_NN with_IN MCC-478_NP showed_VBD no_DT significant_JJ selectivity_NN between_IN the_DT cytotoxicity_NN against_IN mock-infected_JJ MT-4_NP cells_NNS and_CC the_DT inhibition_NN of_IN HIV-induced_JJ cytopathic_JJ effect_NN ,_, e.g._FW ,_, 16_CD and_CC 11_CD %_NN ,_, respectively_RB ,_, even_RB at_IN the_DT highest_JJS concentration_NN ._SENT The_DT EC50s_NP and_CC CC50s_NP of_IN the_DT test_NN compounds_NNS in_IN MT-4_NP cells_NNS are_VBP summarized_VBN in_IN Table_NP ._SENT These_DT results_NNS suggested_VBD that_IN anti-HIV_NP activity_NN of_IN MCC-478_NP was_VBD much_RB weaker_JJR than_IN anti-HBV_NP activity_NN ,_, while_IN PMEA_NP retained_VBD anti-HBV_NP and_CC anti-HIV_NP activity_NN ._SENT Effect_NN of_IN MCC-478_NP on_IN mitochondrial_JJ DNA_NN content_NN ._SENT |_SYM Therapies_NP with_IN nucleoside_NN analogues_NNS sometimes_RB cause_VBP mitochondrial_JJ dysfunction_NN ,_, which_WDT could_MD be_VB derived_VBN from_IN incorporation_NN of_IN the_DT nucleoside_NN analogue_NN into_IN mitochondrial_JJ DNA_NN or_CC reduction_NN in_IN mitochondrial_JJ DNA_NN content_NN ._SENT In_IN this_DT study_NN ,_, the_DT effects_NNS of_IN MCC-478_NP and_CC its_PP$ hydrolyzed_VBN derivatives_NNS on_IN mitochondrial_JJ DNA_NP content_NN were_VBD examined_VBN ,_, using_VBG 2',3'-dideoxycytidine_JJ (_( ddC_NN )_) as_IN a_DT positive_JJ control_NN ._SENT HepG2_JJ cells_NNS were_VBD treated_VBN with_IN each_DT test_NN compound_NN at_IN a_DT final_JJ concentration_NN of_IN 0.1_CD ,_, 1.0_CD ,_, or_CC 10_CD muM_NN for_IN 8_CD days_NNS ._SENT Mitochondrial_JJ DNA_NN content_NN was_VBD examined_VBN by_IN dot_NN blot_NN hybridization_NN ._SENT Treatment_NN with_IN MCC-478_NP ,_, M-1_NP ,_, M-2_NP ,_, or_CC PMEA_NP showed_VBD no_DT reduction_NN in_IN mitochondrial_JJ DNA_NN content_NN ,_, even_RB though_IN treatment_NN with_IN ddC_NN at_IN every_DT concentration_NN reduced_VBD mitochondrial_JJ DNA_NN content_NN to_TO nearly_RB half_JJ that_IN of_IN the_DT untreated_JJ control_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Inhibitory_JJ effects_NNS of_IN MCC-478_NP ,_, PMEA_NP ,_, and_CC lamivudine_NP against_IN HBV_NP replication_NN in_IN HB611_JJ cells_NNS ._SENT Inhibitory_JJ effects_NNS of_IN MCC-478_NP ,_, PMEA_NP ,_, and_CC lamivudine_NP against_IN HBV_NP replication_NN in_IN HB611_JJ cells_NNS ._SENT Cells_NNS were_VBD treated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN test_NN compound_NN for_IN 8_CD days_NNS and_CC harvested_VBN on_IN the_DT last_JJ day_NN of_IN culture_NN ._SENT After_IN total_JJ cellular_JJ DNA_NN was_VBD prepared_VBN ,_, HBV_NP DNAs_NP derived_VBD from_IN both_DT replication_NN intermediates_NNS and_CC integrated_JJ HBV_NP genome_NN were_VBD detected_VBN and_CC analyzed_VBN by_IN Southern_NP blotting_VBG ._SENT Percent_NN control_NN values_NNS were_VBD calculated_VBN from_IN the_DT untreated_JJ controls_NNS (_( U_NP )_) ._SENT The_DT bands_NNS derived_VBN from_IN integrated_JJ HBV_NP are_VBP indicated_VBN by_IN the_DT arrows_NNS ._SENT The_DT mean_JJ value_NN at_IN each_DT concentration_NN is_VBZ plotted_VBN on_IN the_DT graph_NN ,_, and_CC the_DT standard_JJ deviations_NNS are_VBP indicated_VBN by_IN the_DT error_NN bars_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Comparison_NN of_IN the_DT inhibitory_JJ effects_NNS of_IN MCC-478_NP ,_, M-1_NP ,_, M-2_NP ,_, and_CC F-1_NP against_IN HBV_NP replication_NN in_IN HB611_JJ cells_NNS ._SENT Comparison_NN of_IN the_DT inhibitory_JJ effects_NNS of_IN MCC-478_NP ,_, M-1_NP ,_, M-2_NP ,_, and_CC F-1_NP against_IN HBV_NP replication_NN in_IN HB611_JJ cells_NNS ._SENT Cells_NNS were_VBD treated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN test_NN compound_NN for_IN 8_CD days_NNS ._SENT Anti-HBV_NP activity_NN was_VBD evaluated_VBN as_IN indicated_VBN in_IN the_DT legend_NN to_TO Fig._NN ._SENT The_DT mean_JJ value_NN at_IN each_DT concentration_NN is_VBZ plotted_VBN on_IN the_DT graph_NN ,_, and_CC the_DT standard_JJ deviations_NNS are_VBP indicated_VBN by_IN the_DT error_NN bars_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM Effects_NN of_IN MCC-478_NP and_CC its_PP$ derivatives_NNS on_IN mitochondrial_JJ DNA_NN content_NN in_IN HepG2_JJ cells_NNS ._SENT Effects_NNS of_IN MCC-478_NP and_CC its_PP$ derivatives_NNS on_IN mitochondrial_JJ DNA_NN content_NN in_IN HepG2_JJ cells_NNS ._SENT Cells_NNS were_VBD treated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN test_NN compound_NN for_IN 8_CD days_NNS and_CC harvested_VBN on_IN the_DT last_JJ day_NN of_IN culture_NN ._SENT After_IN total_JJ cellular_JJ DNA_NN was_VBD prepared_VBN ,_, mitochondrial_JJ DNA_NN content_NN in_IN 2.5_CD mug_NN of_IN total_JJ cellular_JJ DNA_NN was_VBD evaluated_VBN by_IN dot_NN blot_NN analysis_NN ._SENT The_DT DNAs_NP from_IN nuclei_NNS (_( Nuc_NP )_) and_CC mitochondrial_JJ (_( Mt_NN )_) fractions_NNS of_IN HepG2_JJ cells_NNS are_VBP indicated_VBN by_IN the_DT arrows_NNS ._SENT Percent_NN control_NN values_NNS were_VBD calculated_VBN from_IN the_DT untreated_JJ controls_NNS ._SENT The_DT mean_JJ value_NN at_IN each_DT concentration_NN is_VBZ plotted_VBN on_IN the_DT graph_NN ,_, and_CC the_DT standard_JJ deviations_NNS are_VBP indicated_VBN by_IN the_DT error_NN bars_NNS ._SENT TABLE_NN 1_CD |_SYM Summary_NN of_IN the_DT antiviral_JJ and_CC cytotoxic_JJ effects_NNS of_IN the_DT test_NN compounds_VBZ MCC-478_NP is_VBZ a_DT novel_JJ phosphonomethoxyethylpurine_NN derivative_NN which_WDT has_VBZ an_DT arylthio_NN group_NN at_IN position_NN 6_CD of_IN the_DT purine_NN base_NN ._SENT Also_RB ,_, MCC-478_NP has_VBZ 2-aminopurine_JJ nucleobase_NN structure_NN ,_, which_WDT indicates_VBZ that_IN it_PP is_VBZ more_RBR closely_RB related_VBN to_TO 9-[2-(phosphonomethoxy)ethyl]guanine_VB (_( PMEG_NP )_) than_IN to_TO PMEA_NP ._SENT However_RB ,_, introduction_NN of_IN the_DT arylthio_NN group_NN at_IN position_NN 6_CD of_IN the_DT 2-aminopurine_JJ base_NN has_VBZ been_VBN demonstrated_VBN to_TO endow_VB the_DT purine_NN base_NN with_IN a_DT higher_JJR specificity_NN against_IN HBV_NP and_CC low_JJ cytotoxicity_NN comparable_JJ to_TO that_DT of_IN PMEA_NP ,_, while_IN PMEG_NP is_VBZ known_VBN to_TO have_VB higher_JJR cytotoxicity_NN than_IN PMEA_NP ._SENT These_DT results_NNS suggest_VBP that_IN substitution_NN at_IN position_NN 6_CD of_IN the_DT purine_NN base_NN may_MD alter_VB the_DT biological_JJ and_CC toxicological_JJ profiles_NNS of_IN the_DT phosphonomethoxyethyl_NN purine_NN derivatives_NNS ._SENT It_PP was_VBD reported_VBN that_IN adefovir_NN dipivoxil_NN is_VBZ primarily_RB hydrolyzed_VBN to_TO the_DT monoester_NN form_NN and_CC is_VBZ further_RBR metabolized_VBN to_TO adefovir_NP (_( PMEA_NP )_) in_IN the_DT presence_NN of_IN either_DT cells_NNS or_CC serum_NN ._SENT This_DT finding_NN may_MD mean_VB that_IN there_EX was_VBD an_DT esterase_NN to_TO hydrolyze_VB both_DT bis(pivaloyloxymethyl)_NN and_CC mono(pivaloyloxymethyl)_JJ ester_NN forms_NNS in_IN both_DT serum_NN and_CC cells_NNS ._SENT In_IN the_DT case_NN of_IN MCC-478_NP ,_, which_WDT is_VBZ a_DT bis(2,2,2-trifluroroethyl)_JJ ester_NN ,_, it_PP was_VBD hydrolyzed_VBN to_TO only_RB the_DT monoester_NN form_NN ,_, even_RB in_IN the_DT presence_NN of_IN serum_NN from_IN humans_NNS or_CC rats_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN addition_NN ,_, major_JJ metabolites_NNS in_IN rats_NNS and_CC monkeys_NNS were_VBD found_VBN to_TO be_VB the_DT monoester_NN forms_NNS of_IN MCC-478_NP (_( M-1_NP and_CC M-2_NP )_) ,_, rather_RB than_IN the_DT free_JJ phosphonic_JJ acid_NN form_NN (_( F-1_NP )_) (_( Y._NP Yamaguchi_NP ,_, personal_JJ communication_NN )_) ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT free_JJ phosphonic_JJ acid_NN form_NN ,_, PMEA_NP ,_, was_VBD identified_VBN as_IN the_DT major_JJ metabolite_NN in_IN sera_NN from_IN the_DT animals_NNS given_VBN adefovir_NN dipivoxil_NN orally_RB ._SENT This_DT speculated_VBN difference_NN of_IN metabolites_NNS between_IN MCC-478_NP and_CC adefovir_NN dipivoxil_NN in_IN vivo_RB suggested_VBN the_DT necessity_NN of_IN examining_VBG the_DT antiviral_JJ activities_NNS of_IN these_DT metabolites_NNS in_IN order_NN to_TO estimate_VB their_PP$ efficacy_NN in_IN vivo_RB ._SENT Here_RB ,_, not_RB only_RB the_DT monoester_NN forms_NNS but_CC also_RB the_DT free_JJ phosphonic_JJ acid_NN form_NN were_VBD recognized_VBN to_TO have_VB antiviral_JJ activities_NNS similar_JJ to_TO that_DT of_IN MCC-478_NP in_IN HB611_NP cells_NNS ._SENT The_DT anti-HBV_NP activities_NNS of_IN these_DT MCC-478_NP derivatives_NNS were_VBD high_JJ enough_RB to_TO suggest_VB that_IN they_PP could_MD contribute_VB to_TO in_IN vivo_JJ efficacy_NN of_IN MCC-478_NP ._SENT These_DT results_NNS also_RB indicated_VBD that_IN the_DT mono(2,2,2-trifluoroethyl)_JJ ester_NN forms_NNS of_IN MCC-478_NP may_MD be_VB hydrolyzed_VBN only_RB within_IN the_DT cell_NN and_CC further_RBR metabolized_VBD to_TO an_DT active_JJ form_NN of_IN MCC-478_NP ._SENT In_IN addition_NN to_TO the_DT antiviral_JJ profile_NN of_IN MCC-478_NP ,_, it_PP was_VBD also_RB shown_VBN that_IN the_DT cytotoxic_JJ effects_NNS of_IN MCC-478_NP and_CC its_PP$ hydrolyzed_VBN derivatives_NNS were_VBD quite_RB low_JJ ._SENT It_PP may_MD also_RB be_VB important_JJ to_TO evaluate_VB mitochondrial_JJ toxicity_NN to_TO understand_VB the_DT biological_JJ profile_NN of_IN a_DT nucleotide_NN analogue_NN ,_, since_IN long-term_JJ treatment_NN with_IN antiviral_JJ nucleoside_NN analogues_NNS could_MD give_VB rise_NN to_TO delayed_JJ and_CC possibly_RB severe_JJ mitochondrial_JJ toxicity_NN ._SENT Nucleoside_NN and_CC nucleotide_NN analogs_NNS can_MD be_VB classified_VBN into_IN two_CD types_NNS on_IN the_DT basis_NN of_IN their_PP$ mechanism_NN of_IN mitochondrial_JJ toxicity_NN ._SENT The_DT first_JJ type_NN of_IN nucleoside_NN analogue_NN ,_, such_JJ as_IN fialuridine_NN ,_, has_VBZ a_DT 3'-hydroxyl_JJ group_NN (_( 3'-OH_NP )_) ,_, and_CC mitochondrial_JJ toxicity_NN is_VBZ associated_VBN with_IN nucleoside_NN incorporation_NN into_IN the_DT mitochondrial_JJ DNA_NN ._SENT The_DT second_JJ type_NN of_IN nucleoside_NN analogue_NN ,_, such_JJ as_IN ddC_NN ,_, does_VBZ not_RB have_VB a_DT 3'-OH_JJ group_NN ,_, and_CC mitochondrial_JJ toxicity_NN is_VBZ associated_VBN with_IN reduced_VBN mitochondrial_JJ DNA_NN content_NN by_IN chain_NN termination_NN ._SENT Since_IN MCC-478_NP and_CC its_PP$ hydrolyzed_VBN derivatives_NNS do_VBP not_RB have_VB 3'-OH_JJ ,_, they_PP may_MD belong_VB to_TO the_DT latter_JJ type_NN of_IN nucleoside_NN analogues_NNS ._SENT However_RB ,_, as_IN shown_VBN in_IN Fig._NN ,_, there_EX was_VBD no_DT evidence_NN of_IN inhibition_NN of_IN mitochondrial_JJ DNA_NN replication_NN ._SENT This_DT lack_NN of_IN evidence_NN of_IN inhibition_NN may_MD mean_VB that_IN MCC-478_NP and_CC its_PP$ metabolites_NNS did_VBD not_RB have_VB inhibitory_JJ activity_NN against_IN DNA_NP polymerase_NN gamma_NN ._SENT A_DT chain-terminating_VBG analysis_NN using_VBG DNA_NP polymerase_NN alpha_NN also_RB revealed_VBD that_IN neither_DT F-1_NP nor_CC its_PP$ diphosphate_NN showed_VBD chain-terminating_VBG activity_NN against_IN DNA_NP polymerase_NN alpha_NN ;_: however_RB ,_, PMEA_NP diphosphate_NN was_VBD thought_VBN to_TO have_VB chain-terminating_JJ activity_NN at_IN the_DT same_JJ concentrations_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS emphasize_VBP the_DT specific_JJ antiviral_JJ profiles_NNS of_IN MCC-478_NP and_CC its_PP$ derivatives_NNS ._SENT Interestingly_RB ,_, the_DT diphosphates_NNS derived_VBN from_IN MCC-478_NP were_VBD not_RB found_VBN intracellularly_RB ,_, so_RB far_RB as_IN we_PP tried_VBD ._SENT While_IN there_EX is_VBZ a_DT possibility_NN that_IN the_DT diphosphates_NNS might_MD be_VB a_DT very_RB potent_JJ and_CC selective_JJ inhibitor_NN of_IN hepadnavirus_NN polymerase_NN ,_, MCC-478_NP and_CC its_PP$ derivatives_NNS might_MD not_RB require_VB phosphorylation_NN for_IN biological_JJ activity_NN ._SENT More_JJR studies_NNS of_IN intracellular_JJ metabolism_NN and_CC active_JJ metabolites_NNS would_MD be_VB needed_VBN to_TO elucidate_VB the_DT mechanisms_NNS of_IN MCC-478_NP antiviral_JJ activity_NN ._SENT Lamivudine_NP is_VBZ the_DT first_RB approved_VBN nucleoside_NN analogue_NN for_IN treatment_NN of_IN HBV_NP infection_NN ._SENT It_PP is_VBZ known_VBN to_TO have_VB potent_JJ activity_NN against_IN both_DT HBV_NP and_CC HIV_NP replication_NN ._SENT However_RB ,_, the_DT rapid_JJ emergence_NN of_IN viruses_NNS resistant_JJ to_TO lamivudine_NP in_IN HIV-infected_JJ patients_NNS is_VBZ also_RB known_VBN ,_, even_RB with_IN short-term_JJ therapy_NN ,_, and_CC recently_RB a_DT similar_JJ phenomenon_NN was_VBD observed_VBN with_IN lamivudine_NP monotherapy_NN ._SENT Most_RBS lamivudine-resistant_JJ virus_NN strains_NNS have_VBP methionine_NN (_( M_NP )_) substituted_VBD for_IN isoleucine_NN (_( I_PP )_) or_CC valine_NN (_( V_CD )_) on_IN the_DT YMDD_NP (_( tyrosine-methionine-aspartate-aspartate_NN )_) motif_NN in_IN catalytic_JJ domains_NNS of_IN HIV_NP polymerase_NN and_CC hepadnavirus_NN polymerase_NN ._SENT Another_DT drug-resistant_JJ substitution_NN of_IN leucine_NN (_( L_NP )_) to_TO M_NP in_IN B_NP domain_NN (_( L528M_NP )_) is_VBZ reported_VBN from_IN a_DT clinical_JJ trial_NN of_IN famciclovir_NN in_IN HBV-infected_JJ patients_NNS ._SENT The_DT L528M_NP mutation_NN frequently_RB accompanies_VBZ the_DT YMDD_JJ mutation_NN ,_, and_CC HBV_NP carrying_VBG these_DT two_CD mutations_NNS is_VBZ cross-resistant_JJ to_TO lamivudine_NP and_CC famciclovir_NP ._SENT In_IN the_DT case_NN of_IN HIV_NP ,_, a_DT steric_JJ hindrance_NN between_IN the_DT mutant_JJ amino_NN acid_NN side_NN chain_NN and_CC lamivudine_NN triphosphate_NN is_VBZ suggested_VBN from_IN the_DT molecular_JJ model_NN analysis_NN of_IN comparisons_NNS of_IN crystal_NN structures_NNS of_IN the_DT YMDD_JJ mutant_JJ and_CC wild-type_JJ HIV_NP polymerases_NNS with_IN or_CC without_IN double-strand_NN DNA_NN ._SENT Moreover_RB ,_, this_DT molecular_JJ model_NN suggested_VBD that_IN a_DT steric_JJ hindrance_NN between_IN the_DT mutant_JJ amino_NN acid_NN side_NN chain_NN and_CC the_DT lamivudine_NP sugar_NN ring_NN might_MD be_VB expected_VBN in_IN nucleoside_NN analogues_NNS with_IN beta-l-_NN ring_NN configurations_NNS ._SENT In_IN the_DT case_NN of_IN HBV_NP ,_, a_DT recent_JJ study_NN reporting_VBG molecular_JJ modeling_NN analysis_NN using_VBG the_DT HBV_NP polymerase_NN homology_NN model_NN also_RB supports_VBZ this_DT concept_NN ._SENT Ono_NP et_FW al._FW evaluated_VBN the_DT inhibitory_JJ effects_NNS of_IN a_DT panel_NN of_IN 11_CD nucleoside_NN and_CC nucleotide_NN analogues_NNS on_IN HBVs_NP with_IN one_CD or_CC two_CD mutations_NNS by_IN in_IN vitro_NN full-length_JJ HBV_NP DNA_NP transfection_NN and_CC found_VBD that_IN only_RB a_DT few_JJ nucleoside_NN analogues_NNS ,_, including_VBG PMEA_NP ,_, are_VBP active_JJ against_IN lamivudine-resistant_JJ HBVs_NP ._SENT Since_IN MCC-478_NP was_VBD shown_VBN to_TO be_VB a_DT novel_JJ nucleotide_NN analogue_NN having_VBG potent_JJ and_CC selective_JJ anti-HBV_NP activity_NN ,_, even_RB if_IN it_PP was_VBD a_DT derivative_NN of_IN phosphonomethoxyethylpurine_NN ,_, like_IN PMEA_NP ,_, MCC-478_NP should_MD be_VB further_RBR examined_VBN for_IN an_DT inhibitory_JJ profile_NN against_IN drug-resistant_JJ HBVs_NP ,_, including_VBG lamivudine-resistant_JJ HBVs_NP ._SENT The_DT aim_NN of_IN this_DT work_NN was_VBD to_TO evaluate_VB MCC-478_NP and_CC its_PP$ derivatives_NNS as_IN potent_JJ and_CC specific_JJ agents_NNS for_IN the_DT treatment_NN of_IN HBV_NP infections_NNS ._SENT Although_IN many_JJ studies_NNS have_VBP to_TO be_VB done_VBN to_TO understand_VB the_DT mechanism_NN of_IN action_NN ,_, toxicological_JJ pharmocokinetic_JJ profiles_NNS ,_, and_CC so_RB on_RB ,_, MCC-478_NP could_MD be_VB a_DT promising_JJ new_JJ anti-HBV_NN agent_NN ._SENT 